It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.02.18.22271193;](https://doi.org/10.1101/2022.02.18.22271193) this version posted February 21, 2022. The copyright holder for this preprint

1 **Resurgence of malaria in Uganda despite sustained indoor residual spraying and repeated** 2 **long lasting insecticidal net distributions** 3

- 4 Adrienne Epstein^{1,2}, Catherine Maiteki-Ssebuguzi³, Jane F. Namuganga⁴, Joaniter I. 5 Nankabirwa^{4,5}, Samuel Gonahasa⁴, Jimmy Opigo³, Sarah G. Staedke⁶, Damian Rutazaana³, 6 Emmanuel Arinaitwe⁴, Moses R. Kamya^{4,5}, Samir Bhatt^{7,8}, Isabel Rodríguez-Barraquer⁹, Bryan 7 Greenhouse⁹, Martin J. Donnelly¹, Grant Dorsey⁹ 8 ¹ Department of Vector Biology, Liverpool School of Tropical Medicine, Liverpool, UK 10 ² Department of Epidemiology and Biostatistics, University of California San Francisco, San 12 Francisco, California, United States of America 13 ³ 14 ³ National Malaria Control Division, Ministry of Health, Kampala, Uganda 15 ⁴ Infectious Diseases Research Collaboration, Kampala, Uganda 17 ⁵ 18 Makerere University, College of Health Sciences, Kampala, Uganda 19 ⁶ 20 ⁶ London School of Hygiene and Tropical Medicine, London, United Kingdom 21 ⁷ Department of Infectious Disease Epidemiology, Imperial College, St Mary's Hospital, London, 23 UK 24 ⁸ 25 Section of Epidemiology, Department of Public Health, University of Copenhagen, 26 Copenhagen, Denmark 27 9 28 Department of Medicine, University of California San Francisco, San Francisco, California, 29 United States of America 30 31 32 **Corresponding author:** 33 Adrienne Epstein 34 Liverpool School of Tropical Medicine 35 Pembroke Pl, Liverpool L3 5QA 36 Adrienne.Epstein@lstmed.ac.uk
- 37

38 **Abstract**

49

51 **Introduction**

52 Major gains have been made in reducing the burden of malaria in sub-Saharan Africa over the 53 past two decades, resulting in a 44% decline in malaria deaths between 2000 and 2019.^{1,2} 54 However, progress has slowed in recent years, particularly in highest burden countries.¹ A 55 majority of the decline in malaria burden has been attributed to vector control interventions, 56 including long-lasting insecticidal nets (LLINs) and indoor residual spraying of insecticide 57 (IRS). Scale-up of LLINs coverage has occurred rapidly, with the proportion of households in 58 sub-Saharan Africa with at least one LLIN increasing from 5% in 2000 to 68% in 2019.¹ 59 Conversely, the percent of at-risk populations covered by IRS has been much lower and even 60 declined from 5% in 2010 to 2% in 2019.¹ Challenges to the scale-up of IRS coverage include high cost, complex implementation logistics, and community acceptance.³ Furthermore, evidence 62 from controlled trials is mixed on the added benefit of implementing IRS in communities where 63 LLIN coverage is high. 4^4

64

65 Uganda is illustrative of high burden countries where progress in reducing malaria burden has δ slowed in recent years.¹ The Ugandan Ministry of Health has made a strong commitment to 67 ensuring high LLIN coverage, delivering LLINs through 3 universal coverage campaigns (UCC) 68 taking place in 2013-2014, 2017-2018, and 2020-21. These campaigns have been successful: for 69 example, in 2018-2019, 83% of households reported owning at least one LLIN, the highest 70 coverage globally.⁵ IRS was reintroduced into Uganda in 2006 for the first time since the 1960s, 71 however, geographic coverage of IRS to date has been much lower than LLINs. From 2007 to 72 2014, IRS was implemented in 10 districts in Northern Uganda initially using pyrethroid insecticides and later switching to a carbamate.⁶ In 2014, the IRS campaign was moved to 14

80

81 In this study, we use data from a network of health facility-based malaria surveillance sites to 82 examine the impact of sustained IRS in the 5 districts mentioned above. This study had two 83 objectives. First (Objective 1), to estimate the impact of IRS on malaria burden in 5 districts 84 relative to a baseline period before IRS was initiated after extending our prior analysis⁷ to the 6th 85 and $7th$ years of sustained IRS (January 2020 through October 2021). This extended evaluation 86 period coincided with a shift in insecticide formulations from the organophosphate pirimiphos-87 methyl (Actellic 300CS®) to products containing the active ingredient clothianidin alone 88 (SumiShield®) or combined with deltamethrin (Fludora® Fusion WP-SB), the beginning of the 89 COVID-19 pandemic, and the third LLIN UCC (2020-2021). Second (Objective 2), we 90 compared temporal changes in malaria burden during the $6th$ and $7th$ years of sustained IRS 91 (January 2020 through October 2021) at the 5 sites receiving sustained IRS to 10 sites in 92 neighboring districts that have not received IRS since 2017.

93

94 **Results**

95 **Study Objective 1**

medRxiv preprint doi: [https://doi.org/10.1101/2022.02.18.22271193;](https://doi.org/10.1101/2022.02.18.22271193) this version posted February 21, 2022. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has grante

109 **Figure 1. Malaria case counts and vector control interventions over time at 5 IRS sites.** The

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2022.02.18.22271193;](https://doi.org/10.1101/2022.02.18.22271193) this version posted February 21, 2022. The copyright holder for this preprint

- 113 in Figure 2 and in Supplemental Table 1. These results show there was an initial 52% reduction
- 114 in malaria burden in months 1 through 36 of sustained IRS (adjusted IRR = 0·48, 95% CI 0·36-
- 115 0·64), followed by a continued improvement to an 84% reduction in burden in months 37
- 116 through 60 of sustained IRS (adjusted IRR = 0.16 , 95% CI 0 0.12 -0 0.22). In months 61 through 72,
- 117 however, malaria burden increased and was only 43% lower than the baseline period before IRS
- 118 was implemented (adjusted IRR = 0·57, 95% CI 0·44-0·74). During months 73 through 81 after
- 119 the initiation of IRS, there was a trend towards a higher malaria burden than the pre-IRS period
- 120 (adjusted IRR = 1·39, 95% CI 0·97-1·97). These results were consistent when including only
- 121 laboratory-confirmed cases unadjusted for testing rate as the model outcome (Supplemental
- 122 Figure 1) and when repeating the analysis leaving out the 2 sites that halted IRS campaigns after
- 123 2020 (Orum and Alebtong) (Supplemental Figure 2).
- 124 **Figure 2. Adjusted IRR from multilevel negative binomial model comparing the period**
- 125 **after IRS was initiated to the period before IRS was initiated.** Vertical bars represent the 95% ed
n
-
2, S
r
f
f
f
f
f
f
f
f
- 126 CI around adjusted IRR. Effect estimates in grey are published previously.

128

129 **Study Objective 2**

130 Across the 15 sites over a 22 month period (January 2020 through October 2021) included in the 131 analysis for Objective 2, 583,344 outpatient visits were recorded (Table 2). From January 2020 132 through December 2020, average monthly cases at IRS sites ranged from 64-594 and TPR 133 ranged from 10·9%-51·0%. From January 2021 through October 2021, these figures increased to 134 371-849 and 43·4%-60·1%, respectively. Average monthly cases increased in 4 of the 5 IRS sites 135 comparing January 2020 through December 2020 to January 2021 through October 2021, with 136 the exception of Dokolo (the first site to switch to IRS with a clothianidin-based formulation in 137 2019), which already experienced a large increase in monthly malaria cases by January 2020. 138 139 In sites that had not received IRS recently, average monthly cases from January 2020 through 140 December 2020 ranged from 518-1,068 and TPR from 47·5%-71·1%. These figures decreased to 141 251-716 and 32·5%-50·4%, respectively, from January 2021 through October 2021. Figure 3 142 shows plots of laboratory-confirmed malaria cases and the timing of the recent LLIN distribution 143 across the 10 non-IRS sites from January 2020 through October 2021. These figures indicate a 144 substantial increase in cases the first year of observation for some sites, but a general downward 145 trend in cases across the 10 sites over the 22 month study period for Objective 2. 146

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license . medRxiv preprint doi: [https://doi.org/10.1101/2022.02.18.22271193;](https://doi.org/10.1101/2022.02.18.22271193) this version posted February 21, 2022. The copyright holder for this preprint

147 **Figure 3. Malaria case counts and vector control interventions over time at 10 sites that** 148 **have not received IRS recently.**

150 Figure 4 shows the mean number of cases across the 5 IRS sites and the 10 sites that have not 151 received IRS recently from January 2020 to October 2021 (corresponding to months 60 through 152 81 of IRS for the 5 sites where IRS was initiated and sustained). This figure shows an increase in 153 cases at IRS sites, particularly in the latter half of the observation window, while cases at non-154 IRS sites trended downward over the same time period. Figure 4 also shows the adjusted IRR 155 comparing cases at IRS sites to sites that have not received IRS recently. Coefficients and 95% 156 confidence intervals are also presented in Supplemental Table 2. These findings indicate that 157 from January 2020 to November 2020, cases were significantly lower in IRS sites compared to 158 non-IRS sites. From December 2020 onward, the IRR crossed 1, indicating that cases at IRS sites 159 were higher than non-IRS sites, although we could not rule out a null or negative association in 160 these months. These results show that cases were 67% lower in IRS sites than non-IRS sites from 161 January 2020 through December 2020 (adjusted IRR = 0·33, 95% CI 0·17-0·63) and 38% higher in

tes It is made available under a CO-BY-NC-MD 4.0 International license .

COUNIS and Vector control interventions over time at 10 sites that

There is recently.

The manner of cases across the 5 IRS sites and the 10 sites tha

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license . medRxiv preprint doi: [https://doi.org/10.1101/2022.02.18.22271193;](https://doi.org/10.1101/2022.02.18.22271193) this version posted February 21, 2022. The copyright holder for this preprint

- 162 from January through October 2021 (adjusted IRR $= 1.38$, 95% CI 0.90-2.11). Results were
- 163 consistent when including only laboratory-confirmed cases unadjusted for testing as the outcome
- 164 (Supplemental Figure 3).

165 **Figure 4. Mean case counts in 5 IRS sites and 10 non-IRS sites from January 2020 through**

- 166 **July 2021 (left) and adjusted IRR comparing IRS sites to non-IRS sites over the study**
- 167 **period.** Shaded areas represent standard deviations. Vertical bars represent the 95% CI around 168 adjusted IRR.

169

170 **Discussion**

171 We utilized enhanced health facility surveillance data from 5 sites in North-Eastern Uganda that 172 have undergone sustained IRS since 2014 to evaluate the impact of repeated IRS campaigns in 173 their $6th$ and $7th$ years. Our findings point to a resurgence in the burden of malaria at these 5 174 health facilities, despite sustained IRS and repeated LLIN UCCs conducted every 3 years. In the 175 final 9 months of observation (months 61-81 of sustained IRS), malaria burden reached similar 176 levels, and in some instances higher levels, than the period before IRS was initiated in late 2014. 177 We did not observe corresponding increases in burden at 10 surveillance sites in neighboring 178 non-IRS districts that, unlike IRS districts, received "next generation" LLINs over the study 179 period. These findings suggest that in the setting of universal coverage with conventional 180 pyrethroid-only LLINs, the marked benefit of adding sustained IRS over the first five years had

181 been lost over the subsequent 18 months that coincided with a change in active ingredient and 182 the start of the COVID-19 pandemic.

183

184 This study highlights the importance of high quality routine surveillance to monitor the impact of 185 population level malaria control interventions using clinically relevant indicators such as 186 symptomatic cases diagnosed at health facilities. The assessment of vector control interventions 187 often focuses on entomologic outcomes such as mosquito mortality in controlled settings. This is 188 understandable, given that measuring the impact of control interventions on clinical burden in 189 "real world" settings is difficult. Nevertheless, the findings from this analysis underscore the 190 potential feasibility of and need for robust epidemiologic surveillance systems to document the 191 impact of vector control interventions on population health as they are applied. 192 193 Routine surveillance in areas undergoing IRS is particularly necessary because published studies 194 from controlled trials on the added value of IRS in areas with high LLIN coverage has produced 195 mixed results. A recent Cochrane review reported that adding IRS using a "pyrethroid-like" 196 insecticide to LLINs did not provide any benefits, while adding IRS with a "non-pyrethroid-like" 197 insecticide produced mixed results. 4 It is of note that none of the trials that evaluated the impact 198 of adding IRS with a "non-pyrethroid-like" insecticide assessed outcomes beyond two years. 199 More recently, observational studies evaluating the effectiveness of pirimiphos-methyl (Actellic 200 $\,$ 300CS®) in "real world" settings have documented impressive impacts of IRS in Mali^{8,9}, 201 Ghana¹⁰, Zambia¹¹, Kenya¹², and Uganda.⁷ This analysis contributes to observational data on the 202 impacts of sustained IRS beyond 6 years, in the context of the COVID-19 pandemic and a switch

203 to products containing the active ingredient clothianidin.

226 A second potential contributor to the observed resurgence of malaria at sites receiving IRS is the 227 COVID-19 pandemic. An important concern has been the potential for delayed or inadequate 228 implementation of vector control measures due to the pandemic.^{24,25} In Uganda, the LLIN 229 distribution campaign was delayed by 5 months but successfully distributed over 28 million nets, 230 achieving over 90% coverage. Given that the delay in the UCC was country-wide, we do not 231 believe an increase in burden resulting from delayed net distribution would be observed strictly 232 in IRS sites as was the case in this study. The implementation of IRS campaigns did not appear 233 impacted by the COVID-19 pandemic; annual campaigns in 2020 and 2021 were not delayed and 234 coverage remained high (>90%, see Supplemental Table 3). We cannot rule out the potential for 235 undocumented differences in implementation (for example, if spray operators spent less time in 236 homes due to fear of acquiring COVID-19) that may have contributed to the observed 237 resurgence. The pandemic may also have impacted patient behavior; for example, patients may 238 have delayed seeking care for malarial illness which could have led to increased transmission. 239 However, because sites that have not recently received IRS did not observe an increase in 240 transmission, this explanation is less tenable. Furthermore, an analysis assessing the potential 241 impact of the first year of the COVID-19 pandemic at Uganda Malaria Surveillance Program 242 (UMSP) sites found no impact of the pandemic on malaria cases and non-malarial visits at health 243 facilities. 26

244

245 Another potential explanation is a shift in mosquito species composition or mosquito behavior to 246 outdoor biting, circumventing vector control interventions that target indoor biting mosquitoes.²⁷ 247 This, however, would be unlikely to have occurred rapidly and simultaneously at all IRS sites at 248 a pace that would explain the resurgence observed in this study. In addition, this would not

249 explain the observation that the resurgence was observed only in the IRS sites and not in the non-250 IRS sites that only received LLINs, as a shift to outdoor biting would have a negative impact on 251 both IRS and LLINs. Similarly, a shift in the predominant species from *Anopheles gambiae* and 252 *Anopheles funestus* to *Anopheles arabiensis* may have led to a change from predominately indoor to outdoor biting.²⁸ 253 Recent data demonstrate that *Anopheles gambiae* and *Anopheles* 254 *funestus* remain the primary vectors in Uganda¹⁵, but other work has documented the near 255 collapse of *Anopheles gambiae* and *Anopheles funestus* in areas with an LLIN distribution and 256 repeated IRS campaigns. 28

257

258 This study is not without limitations. First, we used an observational study design, with measures 259 of impact based on comparisons made before-and-after the implementation of IRS and 260 comparisons of IRS and non-IRS districts. While cluster randomized controlled trials remain the 261 gold standard design for estimating the impact of IRS, withholding IRS may be unethical, given 262 what is known about its beneficial impacts, particularly in Uganda.⁷ Similarly, comparisons of 263 IRS sites and sites that have not recently received IRS are strictly descriptive, given that districts 264 receiving IRS and not receiving IRS are not exchangeable. Second, while we hypothesize 265 potential mechanisms that may explain the observed resurgence in malaria burden in IRS sites, 266 we cannot rule potential secular trends or other unmeasured contributing factors. For example, 267 while we attempt to control for seasonal effects and climate-related drivers of malaria burden 268 over time, it is certainly possible that more recent months over the observation period correspond 269 to an unusually high burden period in Uganda. However, overall secular trends are an unlikely 270 cause given the contemporaneous decline in malaria burden at nearby non-IRS sites. Third, the 271 outcome for this analysis is limited to case counts of laboratory-confirmed malaria captured at

272 health facilities. We do not have additional data on other metrics of transmission intensity,

273 including entomologic measures, residual efficacy, nor on malaria mortality.

274

- 293 **Methods**
- 294 **Study sites and vector control interventions**

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license . medRxiv preprint doi: [https://doi.org/10.1101/2022.02.18.22271193;](https://doi.org/10.1101/2022.02.18.22271193) this version posted February 21, 2022. The copyright holder for this preprint

314 In the 5 study districts where IRS was first implemented in late 2014, the insecticide formulation 315 initially consisted of a carbamate (bendiocarb) with rounds repeated approximately every 6 316 months until 2016 when the active ingredient was changed to the organophosphate pirimiphos-317 methyl (Actellic 300CS®) administered annually until 2019. In 2019, one study district (Dokolo) 318 received a single round of IRS with SumiShield® 50WG, a new IRS product containing 319 clothianidin. In 2020, all IRS districts began receiving IRS with Fludora® Fusion WP-SB, a new 320 IRS insecticide containing a mixture of clothianidin and deltamethrin. Changes of IRS 321 insecticides were made in accordance with the Ugandan Ministry of Health's insecticide 322 resistance management plan which, in line with WHO recommendations, requires changing IRS 323 formulations every three years to preempt the development of resistance.^{30,31} In two study 324 districts (Otuke and Alebtong), IRS was discontinued in 2021 due to lack of funding. For a

325 complete timeline of all IRS campaigns, including insecticides and coverage, see Supplemental 326 Table 3.

327

328 **Health-facility based surveillance**

329 A network of enhanced malaria surveillance sites embedded in public health facilities was 330 established by UMSP in 2006, as previously described.³² In brief, UMSP currently operates 331 Malaria Reference Centers (MRCs) at 70 level III/IV public health facilities across Uganda. 332 Level III and IV health facilities are parish and sub-county level facilities, respectively, and 333 provide diagnostic testing and treatment free of charge to populations of 20,000 to 100,000 334 people per facility. At MRCs, individual-level data are collected for all outpatients using 335 outpatient registers (HMIS 002) and entered monthly into a database by on-site data entry 336 officers. Information collected includes sociodemographic data (age, sex, and village of 337 residence), whether malaria was suspected, results of laboratory testing for malaria (rapid 338 diagnostic test [RDT] or microscopy), diagnoses (laboratory-confirmed and clinical), and 339 treatments prescribed. UMSP places emphasis on high quality data, ensuring minimal 340 missingness on key variables including age and place of residence, and providing training and 341 materials to maximize diagnostic testing among patients suspected of having malaria. For 342 Objective 1 (to evaluate the impact of IRS on malaria burden in 5 districts over 6·75 of sustained 343 use), we utilized data from 5 MRCs from districts with where IRS was implemented in 2014. 344 These MRCs were selected because they had been active UMSP sites for at least 6 months prior 345 to the initiation of IRS. To compare changes in malaria burden from January 2020 through 346 October 2021 (years 6 & 7 following implementation of IRS) at sites receiving sustained IRS to 347 sites in neighboring districts that have not received IRS recently, we used data from 10 additional

371

391 For Objective 2, models were specified as mixed effects negative binomial regression models 392 with random intercepts for health facility. The binary indicator variable representing whether a 393 site was an IRS site or a non-IRS site was interacted with an indicator variable representing time

- 394 (an indicator representing month/year and, in a separate model, a categorical variable
- 395 representing January 2020-December 2020 and January 2021-October 2021). Coefficients for the
- 396 exposure variable combined with the interaction term were exponentiated to represent the
- 397 incidence rate ratio (IRR) comparing the burden of malaria IRS sites versus non-IRS sites over a
- 398 given period of time. These models test the null hypothesis of no difference between malaria
- 399 burden at IRS sites compared to non-IRS sites, adjusting for seasonal effects and time-varying
- 400 changes in diagnostic testing and care seeking.
- 401

402 **Data availability**

- 403 The datasets generated during and/or analysed during the current study are available in GitHub at
- 404 the URL https://github.com/aeepstein/resurgence-irs-uganda
- 405

406 **Acknowledgements**

- 407 We would like to acknowledge the health workers at the health facilities that contributed data for
- 408 this study. We would like to thank the Ugandan Ministry of Health National Malaria Control
- 409 Division, and USAID President's Malaria Initiative. This work was supported by the National
- 410 Institutes of Health as part of the International Centers of Excellence in Malaria Research
- 411 (ICMER) program (U19AI089674). Funding for this work was also supported by the National
- 412 Institute of Allergy and Infectious Diseases (F31AI150029).
- 413
- 414

415 **Author contributions**

- 416 AE and GD conceived of the study. JFN led the data collection activities with support from
- 417 CMS, JIN, EA, and SG. AE led the data analysis with support from GD, SB, IRB, and BG. AE
- 418 and GD drafted the manuscript with support from CMS, JFN, SGS, IRB, BG, MRK, and MJD.
- 419 All authors contributed to interpretation of the results and edited the manuscript. All authors read
- 420 and approved the final manuscript.

- 422 **Competing Interests**
- 423 The authors declare no competing interests.
- 424

- 469 16 Oxborough, R. M. *et al.* Susceptibility testing of Anopheles malaria vectors with the
- 470 neonicotinoid insecticide clothianidin; results from 16 African countries, in preparation
- 471 for indoor residual spraying with new insecticide formulations. *Malar J* **18**, 264,
- 472 doi:10.1186/s12936-019-2888-6 (2019).
- 473 17 Marti-Soler, H. *et al.* Effect of wall type, delayed mortality and mosquito age on the
- 474 residual efficacy of a clothianidin-based indoor residual spray formulation (SumiShield
- 475 50WG) in southern Mozambique. *PLoS One* **16**, e0248604,
- 476 doi:10.1371/journal.pone.0248604 (2021).
- 477 18 Agossa, F. R. *et al.* Efficacy of a novel mode of action of an indoor residual spraying
- 478 product, SumiShield(R) 50WG against susceptible and resistant populations of
- 479 Anopheles gambiae (s.l.) in Benin, West Africa. *Parasit Vectors* **11**, 293,
- 480 doi:10.1186/s13071-018-2869-6 (2018).
- 481 19 Ngwej, L. M. *et al.* Indoor residual spray bio-efficacy and residual activity of a
- 482 clothianidin-based formulation (SumiShield((R)) 50WG) provides long persistence on
- 483 various wall surfaces for malaria control in the Democratic Republic of the Congo. *Malar*
- 484 *J* **18**, 72, doi:10.1186/s12936-019-2710-5 (2019).
- 485 20 Kweka, E. *et al.* Novel Indoor Residual Spray Insecticide With Extended Mortality
- 486 Effect: A Case of SumiShield 50WG Against Wild Resistant Populations of Anopheles
- 487 arabiensis in Northern Tanzania. *Glob Health Sci Pract* **6**, 758-765, doi:10.9745/GHSP-
- 488 D-18-00213 (2018).
- 489 21 Fongnikin, A. *et al.* Efficacy of Fludora(R) Fusion (a mixture of deltamethrin and
- 490 clothianidin) for indoor residual spraying against pyrethroid-resistant malaria vectors:

491 laboratory and experimental hut evaluation. *Parasit Vectors* **13**, 466,

492 doi:10.1186/s13071-020-04341-6 (2020).

- 493 22 Fuseini, G., Phiri, W. P., von Fricken, M. E., Smith, J. & Garcia, G. A. Evaluation of the
- 494 residual effectiveness of Fludora fusion WP-SB, a combination of clothianidin and
- 495 deltamethrin, for the control of pyrethroid-resistant malaria vectors on Bioko Island,
- 496 Equatorial Guinea. *Acta Trop* **196**, 42-47, doi:10.1016/j.actatropica.2019.05.006 (2019).
- 497 23 Agossa, F. R. *et al.* Small-scale field evaluation of the efficacy and residual effect of
- 498 Fludora((R)) Fusion (mixture of clothianidin and deltamethrin) against susceptible and
- 499 resistant Anopheles gambiae populations from Benin, West Africa. *Malar J* **17**, 484,
- 500 doi:10.1186/s12936-018-2633-6 (2018).
- 501 24 Seelig, F. *et al.* The COVID-19 pandemic should not derail global vector control efforts. 502 *PLoS Negl Trop Dis* **14**, e0008606, doi:10.1371/journal.pntd.0008606 (2020).
- 503 25 Guerra, C. A. *et al.* Malaria vector control in sub-Saharan Africa in the time of COVID-
- 504 19: no room for complacency. *BMJ Glob Health* **5**, doi:10.1136/bmjgh-2020-003880 505 (2020).
- 506 26 Namuganga, J. F. *et al.* Impact of COVID-19 on routine malaria indicators in rural
- 507 Uganda: an interrupted time series analysis. *Malar J* **20**, 475, doi:10.1186/s12936-021-
- 508 04018-0 (2021).
- 509 27 Lindsay, S. W., Thomas, M. B. & Kleinschmidt, I. Threats to the effectiveness of
- 510 insecticide-treated bednets for malaria control: thinking beyond insecticide resistance.
- 511 *Lancet Glob Health* **9**, e1325-e1331, doi:10.1016/S2214-109X(21)00216-3 (2021).

- 513 Anopheles density and species composition from three areas of Uganda with differing
- 514 malaria endemicity. *Malar J* **20**, 138, doi:10.1186/s12936-021-03675-5 (2021).
- 515 29 Staedke, S. G. *et al.* Effect of long-lasting insecticidal nets with and without piperonyl
- 516 butoxide on malaria indicators in Uganda (LLINEUP): a pragmatic, cluster-randomised
- 517 trial embedded in a national LLIN distribution campaign. *Lancet* **395**, 1292-1303,
- 518 doi:10.1016/S0140-6736(20)30214-2 (2020).
- 519 30 WHO. Global Plan for Inescticide Resistance Management in Malaria Vectors. (2012).
- 520 31 Ministry of Health. The Uganda Malaria Reduction Strategic Plan 2014-2020. (Kampala,
- 521 Uganda, 2014).
- 522 32 Sserwanga, A. *et al.* Improved malaria case management through the implementation of a
- 523 health facility-based sentinel site surveillance system in Uganda. *PLoS One* **6**, e16316,
- 524 doi:10.1371/journal.pone.0016316 (2011).
- 525 33 Funk, C. *et al.* The climate hazards infrared precipitation with stations--a new
- 526 environmental record for monitoring extremes. *Sci Data* **2**, 150066,
- 527 doi:10.1038/sdata.2015.66 (2015).

